PharmAust teams up with leading cancer research institute on MPL drug candidate
Published 15-MAR-2018 13:25 P.M.
|
1 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
PharmAust (ASX:PAA), a clinical-stage oncology company, has revealed its new collaboration with Dr Doug Fairlie, a leading cancer researcher based at Victoria’s prestigious Olivia Newton-John Cancer Research Institute (ONJCRI).
This collaboration was formed in order to better understand how PAA’s leading clinical candidate, Monepantel (MPL), is able to kill cancer cells.
An additional critical aim here is to identify drug combinations that improve MPL’s potency against different types of cancers.
In turn, these outcomes will be used to support and accelerate MPL’s clinical development strategies in humans and dogs.
Moreover, the collaboration has been awarded a $50,000 Innovation Connections Grant from the Commonwealth Department of Industry, Innovation and Science – a clear recognition of this partnership’s commercial potential.
“We are excited about the potential of this project which builds upon the long-term research interests of our laboratory,” said Dr Fairlie.
The project is in its early stages therefore investors considering this stock for their portfolio, should seek professional financial advice.
PAA CEO, Dr Richard Hopkins, said: “This collaboration will build upon our current understanding of how MPL works. Determining whether MPL has a novel mode of action could unlock substantial commercial value and will also help inform our selection of cancers that will most likely respond to MPL treatment in clinical trials.”
Hopkins added: “We are very pleased about the grant award and particularly delighted to be working with Dr Fairlie and the ONJCRI, which is home to many of Australia’s leading cancer researchers and clinicians.
“The translational capacity of this institute is formidable as it integrates both basic and clinical research with over 200 clinical trials in progress at any one time.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
